Your browser doesn't support javascript.
loading
Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency.
Gothe, Florian; Stremenova Spegarova, Jarmila; Hatton, Catherine F; Griffin, Helen; Sargent, Thomas; Cowley, Sally A; James, William; Roppelt, Anna; Shcherbina, Anna; Hauck, Fabian; Reyburn, Hugh T; Duncan, Christopher J A; Hambleton, Sophie.
Afiliação
  • Gothe F; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom; Department of Pediatrics, Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • Stremenova Spegarova J; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom.
  • Hatton CF; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom.
  • Griffin H; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom.
  • Sargent T; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom.
  • Cowley SA; James & Lillian Martin Centre for Stem Cell Research, Sir William Dunn School of Pathology, Oxford University, Oxford, United Kingdom.
  • James W; James & Lillian Martin Centre for Stem Cell Research, Sir William Dunn School of Pathology, Oxford University, Oxford, United Kingdom.
  • Roppelt A; Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Shcherbina A; Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Hauck F; Department of Pediatrics, Dr von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • Reyburn HT; Department of Immunology and Oncology, Spanish Center for Biotechnology (CNB-CSIC), Madrid, Spain.
  • Duncan CJA; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom; Infection and Tropical Medicine, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. Electronic address:
  • Hambleton S; Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom; Children's Immunology Service, Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. Electronic add
J Allergy Clin Immunol ; 150(4): 955-964.e16, 2022 10.
Article em En | MEDLINE | ID: mdl-35182547
ABSTRACT

BACKGROUND:

Inflammatory phenomena such as hyperinflammation or hemophagocytic lymphohistiocytosis are a frequent yet paradoxical accompaniment to virus susceptibility in patients with impairment of type I interferon (IFN-I) signaling caused by deficiency of signal transducer and activator of transcription 2 (STAT2) or IFN regulatory factor 9 (IRF9).

OBJECTIVE:

We hypothesized that altered and/or prolonged IFN-I signaling contributes to inflammatory complications in these patients.

METHODS:

We explored the signaling kinetics and residual transcriptional responses of IFN-stimulated primary cells from individuals with complete loss of one of STAT1, STAT2, or IRF9 as well as gene-edited induced pluripotent stem cell-derived macrophages.

RESULTS:

Deficiency of any IFN-stimulated gene factor 3 component suppressed but did not abrogate IFN-I receptor signaling, which was abnormally prolonged, in keeping with insufficient induction of negative regulators such as ubiquitin-specific peptidase 18 (USP18). In cells lacking either STAT2 or IRF9, this late transcriptional response to IFN-α2b mimicked the effect of IFN-γ.

CONCLUSION:

Our data suggest a model wherein the failure of negative feedback of IFN-I signaling in STAT2 and IRF9 deficiency leads to immune dysregulation. Aberrant IFN-α receptor signaling in STAT2- and IRF9-deficient cells switches the transcriptional output to a prolonged, IFN-γ-like response and likely contributes to clinically overt inflammation in these individuals.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interferon Tipo I Idioma: En Ano de publicação: 2022 Tipo de documento: Article